Comparative Pharmacology
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus PERIACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus PERIACTIN.
DEXCHLORPHENIRAMINE MALEATE vs PERIACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexchlorpheniramine maleate is a histamine H1 receptor antagonist that competitively blocks the effects of histamine at peripheral H1 receptors, reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction. It also has anticholinergic and sedative properties.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
2 mg orally every 4-6 hours; maximum 12 mg/day
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
None Documented
None Documented
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life is 20-24 hours in healthy adults, allowing once or twice daily dosing. Prolonged in hepatic impairment or elderly.
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Primarily renal (approximately 70-80% as unchanged drug and metabolites, mainly glucuronide conjugates); minor biliary/fecal elimination (20-30%).
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."